CN112043756A - Dialysate of fevervine extract, preparation method and application thereof - Google Patents
Dialysate of fevervine extract, preparation method and application thereof Download PDFInfo
- Publication number
- CN112043756A CN112043756A CN201910488224.4A CN201910488224A CN112043756A CN 112043756 A CN112043756 A CN 112043756A CN 201910488224 A CN201910488224 A CN 201910488224A CN 112043756 A CN112043756 A CN 112043756A
- Authority
- CN
- China
- Prior art keywords
- extract
- dialysate
- fevervine
- ethanol
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a dialysate of fevervine extract, wherein the fevervine extract comprises more than 60 wt% of iridoid compounds, and the iridoid compounds mainly consist of asperulosidic acid, asperuloside, digitonin, paederosidic acid and paederosidic acid methyl ester. The invention also provides a preparation method of the dialysate of the paederia scandens extract and application of the dialysate of the paederia scandens extract in preparing a medicament for reducing uric acid.
Description
Technical Field
The invention relates to a dialysate of paederia scandens extract, a preparation method and application thereof.
Background
Paederia scandens (Lour.) Merr is aerial part or whole plant of Paederia scandens of Rubiaceae, also called herba Paederiae and caulis Kadsurae Longipedunculatae. The paederia scandens is sweet and sour in taste and neutral in nature, enters liver, stomach and large intestine channels, has the effects of promoting digestion, removing food retention, dispelling wind, activating blood circulation, relieving pain and diminishing swelling, is mainly distributed in the southeast coastal areas of China, Yangtze river watershed regions and the like, and is a traditional Chinese medicinal material. Modern pharmacological research proves that the Chinese fevervine herb has a plurality of remarkable effects of resisting inflammation, easing pain, calming, treating digestive system diseases and the like. The paederia scandens comprises iridoid glycosides, flavones, triterpenes, steroids, phenylpropanoids, volatile oil and other natural products.
Chinese patent publication No. CN105287790A discloses a Paederia scandens extract and its application. The fevervine extract mentioned therein contains 60% to 99% of iridoid glycosides, but there is no disclosure of specific compounds of iridoid glycosides contained in the fevervine extract and their contents. Chinese patent publication No. CN101049360 discloses a Chinese medicinal preparation for treating gout and the use of fevervine extract, wherein the mentioned fevervine extract contains paederoside, feveroside, asperuloside, paederoside, deacetylated asperuloside, ursolic acid, sitosterol, fatty acid, fatty alcohol and volatile oil components, but does not disclose the content of the compounds.
The applicant's previous chinese patent publication specifications CN104398619A, CN104435226A and CN104474068A disclose fevervine extract and its use in reducing uric acid, anti-inflammatory and anti-gouty arthritis. On the premise of the Chinese fevervine herb extract disclosed above, the Chinese fevervine herb extract dialysate is obtained by further refining. The iridoid compound contains asperulosidic acid, asperuloside, indirubin, paederosidic acid and methyl paederosidic acid, the content of the total extract is more than 60%, and the iridoid compound has good effect of reducing uric acid.
Disclosure of Invention
The invention obtains a dialysate of the Chinese fevervine herb extract by further refining on the premise of the Chinese fevervine herb extract. Wherein the iridoid contains asperulosidic acid, asperuloside, indirubin, paederosidic acid and paederosidic acid methyl ester, and the content of the total extract of paederosidic acid is more than 60%. The application proves that the dialysate of the paederia scandens extract obtained by the application has better in-vitro uric acid reduction activity compared with the paederia scandens extract.
Thus, in one aspect, the invention provides a dialysate of a fevervine extract, wherein the fevervine extract comprises more than 60 wt% of iridoids, and the iridoids consist essentially of asperulosidic acid, asperuloside, indioside, paederosidic acid methyl ester;
the preparation method comprises the following steps:
a) extracting herba Paederiae with ethanol to obtain extractive solution;
b) concentrating the extracting solution until no alcohol smell exists, performing macroporous adsorption resin chromatography for the first time, sequentially eluting with water and 80-90% ethanol, collecting ethanol eluent, performing reduced pressure concentration until no alcohol smell exists, performing macroporous adsorption resin chromatography for the second time, sequentially eluting with water and 25-35% ethanol, collecting ethanol eluent, and performing reduced pressure concentration to obtain a crude extract of the fevervine herb;
c) loading the herba Paederiae crude extract into polyamide chromatographic column, eluting with water, collecting eluate by stages, and drying under reduced pressure to obtain herba Paederiae extract;
d) dialyzing the fevervine herb extract through a 3500 Da-unit dialysis membrane, and recovering the fraction of small-molecule compounds permeated through the membrane to obtain a dialysate of the fevervine herb extract.
Wherein the small molecule compound moiety comprises asperulosidic acid, asperuloside, diglucoside, paederosidic acid, and paederosidic acid methyl ester.
The inventor surprisingly found that the paederia scandens extract is dialyzed dynamically and statically by a 3500Da dialysis membrane, and the macromolecular compound part and the small molecular compound part permeating out of the membrane are recovered after dialysis. The finding shows that the small molecular compound part of the paederia scandens extract which permeates out of the membrane after dialysis also has very obvious effect of reducing uric acid for the rat with acute hyperuricemia, and the large molecular compound part has no obvious effect of reducing uric acid.
According to a preferred embodiment of the invention, the amount ratio of the fevervine herb to the resin is 1kg of herb, 300ml of macroporous resin after swelling pretreatment by absolute ethyl alcohol is needed.
According to a preferred embodiment of the present invention, the macroporous adsorbent resin is loaded for the first time in step b), and then the macroporous adsorbent resin is sequentially eluted by water and 85% ethanol, and the 85% ethanol eluate is collected.
According to a preferred embodiment of the present invention, the macroporous adsorbent resin is loaded again in step b), and then the macroporous adsorbent resin is sequentially eluted with water and 30% ethanol, and the 30% ethanol eluate is collected.
According to a preferred embodiment of the present invention, the macroporous adsorbent resin in step b) is type D101.
According to a preferred embodiment of the present invention, the column diameter height ratio of the macroporous adsorbent resin in step b) is 1:8 to 1: 12.
According to a preferred embodiment of the invention, the flow rates of the first and second loading in step b) are both 1.0-2.0BV/h and the elution flow rate is 4-6 BV/h.
According to a preferred embodiment of the invention, the polyamide chromatography column in step c) has a column diameter height ratio of 1:8 to 1:12 and a particle size of 30 to 50 mesh.
In a second aspect, the present invention provides a method for preparing a dialysate of fevervine herb extract, comprising the steps of:
a) extracting herba Paederiae with ethanol to obtain extractive solution;
b) concentrating the extracting solution until no alcohol smell exists, performing macroporous adsorption resin chromatography for the first time, sequentially eluting with water and 80-90% ethanol, collecting ethanol eluent, performing reduced pressure concentration until no alcohol smell exists, performing macroporous adsorption resin chromatography for the second time, sequentially eluting with water and 25-35% ethanol, collecting ethanol eluent, and performing reduced pressure concentration to obtain a crude extract of the fevervine herb;
c) loading the herba Paederiae crude extract into polyamide chromatographic column, eluting with water, collecting eluate by stages, and drying under reduced pressure to obtain herba Paederiae extract;
d) dialyzing the fevervine herb extract through a 3500 Da-unit dialysis membrane, and recovering the fraction of small-molecule compounds permeated through the membrane to obtain a dialysate of the fevervine herb extract.
The third aspect of the invention provides the application of the dialysate of the paederia scandens extract in preparing the medicament for reducing the uric acid.
The fourth aspect of the invention provides application of the dialysate of the paederia scandens extract in preparing a medicament for treating gouty arthritis.
The fifth aspect of the invention provides the application of the dialysate of the paederia scandens extract in preparing a medicament for treating hyperuricemia.
The preparation method of the herba Paederiae extract dialysate has the advantages of simple process, reasonable design and little environmental pollution. The method has the advantages of no environmental pollution, less ethanol consumption, lower cost and higher yield, and is suitable for industrial production.
Because the fevervine herb extract disclosed by the invention contains unique components and contents of iridoid compounds in small molecular compound parts which permeate out of membranes after dialysis, the fevervine herb extract has a more remarkable uric acid reducing effect on acute hyperuricemia rats compared with the fevervine herb extract.
Drawings
FIG. 1 is a high performance liquid chromatogram of a dialysate of Paederia scandens extract-1 obtained in example 1 of the present invention.
Wherein, the contents of three compounds in the dialysate of the paederia scandens extract-1 obtained in the embodiment 1 of the invention are respectively shown in the following table:
Detailed Description
Example 1: preparation of Paederia scandens extract-1:
10kg of Yunnan medicinal material (150830), adding 8 times of 95% ethanol, reflux-extracting for 3 times, filtering, mixing the extractive solutions, concentrating under reduced pressure at 60 deg.C until no alcohol smell, adding deionized water to dissolve, centrifuging, collecting supernatant, eluting with macroporous adsorbent resin (the weight ratio of medicinal material to resin is 1kg, 300ml of macroporous resin after swelling pretreatment with anhydrous ethanol), the height ratio of resin column diameter is 1:8, the sample flow rate is 1.0BV/h, after sample application, the elution flow rate is 5.0BV/h, eluting resin column with deionized water for 2BV, discarding flow-through liquid and water eluate, eluting resin column with 85% ethanol for 6BV, collecting eluate of 85% ethanol, concentrating under reduced pressure at 60 deg.C until no alcohol smell, adding deionized water to dissolve, centrifuging, collecting supernatant, the sample application flow rate of macroporous adsorbent resin (the height ratio of resin column diameter is 1:8) is 1.0BV/h, after the sample loading is finished, the elution flow rate is 5.0BV/h, the resin column is eluted by deionized water for 2BV, the flow-through liquid and the water eluent are discarded, the resin column is eluted by 30 percent ethanol for 6BV, the 30 percent ethanol eluent is collected, the pressure reduction concentration is carried out at 60 ℃, and the drying is carried out, thus obtaining the crude extract of the Chinese fevervine herb. Weighing 50g of crude extract of herba Paederiae, dissolving with 100ml of deionized water, loading on polyamide chromatographic column (particle size of 30-50 mesh, height ratio of chromatographic column diameter of 1:10), eluting with deionized water, collecting one part per 1000ml, recovering, collecting the 3 rd part, concentrating under reduced pressure at 60 deg.C, and drying to obtain herba Paederiae extract-1, wherein contents of jacoboside, paederosidic acid methyl ester are respectively: 3.27%, 40.04%, 6.70% and 11.03%.
Example 2: preparation of fevervine extract-2:
taking 10kg of Yunnan medicinal material (150830), adding 10 times of 95% ethanol, reflux-extracting for 3 hours, extracting for 3 times, filtering, combining the extracting solutions, concentrating under reduced pressure at 60 ℃ until no alcohol smell exists, adding deionized water until dissolution is realized, centrifuging, taking supernatant, eluting macroporous adsorption resin (the weight ratio of the medicinal material to the resin is 1kg, 300ml of macroporous resin subjected to swelling pretreatment by the anhydrous ethanol is needed), the height ratio of the resin column diameter is 1:9, the sampling flow rate is 1.0BV/h, after sampling is finished, the eluting flow rate is 5.0BV/h, eluting the resin column with deionized water for 2BV, discarding the flow-through liquid and water eluent, eluting the resin column with 85% ethanol for 6BV, collecting the eluent of 85% ethanol, concentrating under reduced pressure at 60 ℃ until no alcohol smell exists, adding deionized water until dissolution is realized, centrifuging, taking supernatant, eluting the sampling flow rate of the macroporous adsorption resin (the height ratio of the resin column diameter is 1:8) is 1.0BV/h, after the sample loading is finished, the elution flow rate is 5.0BV/h, the resin column is eluted by deionized water for 2BV, the flow-through liquid and the water eluent are discarded, the resin column is eluted by 30 percent ethanol for 6BV, the 30 percent ethanol eluent is collected, the pressure reduction concentration is carried out at 60 ℃, and the drying is carried out, thus obtaining the crude extract of the Chinese fevervine herb. Weighing 50g of herba Paederiae crude extract, dissolving with 100ml of deionized water, loading on polyamide chromatographic column (particle size of 30-50 mesh, height ratio of chromatographic column diameter of 1:10), collecting one part per 1000ml, recovering, collecting the 4 th part, concentrating under reduced pressure at 60 deg.C, and drying to obtain herba Paederiae extract-2, wherein the contents of asperulosidic acid, asperuloside, loganin, paederosidic acid methyl ester are respectively: 3.68%, 41.43%, 5.83% and 11.07%.
Example 3:
weighing Paederia scandens extract obtained in example 2-2, 1.131g, adding 100ml water, dissolving, pouring into 3500Da dialysis membrane, sealing both ends, dialyzing under running water for 24h, recovering macromolecular compounds in dialysis bag, concentrating under reduced pressure at 60 deg.C, and drying to obtain sample 0.33g with yield of 29.18%.
Example 4:
weighing herba Paederiae extract 1, 1.216g obtained in example 1, adding water 100ml, dissolving, pouring into 3500Da dialysis membrane, sealing both ends, dialyzing under running water for 24 hr, recovering macromolecular compounds in dialysis bag, concentrating under reduced pressure at 60 deg.C, and drying to obtain sample 0.236g with yield of 19.41%.
Example 5:
weighing herba Paederiae extract obtained in example 1-1, 1.068g, adding water 100ml, dissolving, pouring into 3500Da unit dialysis membrane, sealing both ends, performing static dialysis in 2L glass beaker for 24 hr, changing water in beaker every 2 hr, standing for six times, and dialyzing overnight. Macromolecular compounds in the dialysis bag are recovered, decompressed and concentrated at 60 ℃, and dried to obtain 0.09g of sample with the yield of 8.43 percent; and recovering the dialyzed small molecular compound, concentrating under reduced pressure at 60 ℃, and drying to obtain 0.94g of a sample with the yield of 88.01%.
Example 6: the uric acid reduction experiment of the dialysate of the paederia scandens extract for treating the rat acute hyperuricemia model caused by potassium oxonate
Instrument and material
1.1 test drugs
1.1.1 samples
Name/abbreviated number: fevervine extract obtained in example 2-2, dialysate of fevervine extract obtained in example 3 (macromolecular compound after dynamic dialysis), fevervine extract obtained in example 5 (small molecular compound after static dialysis), fevervine extract obtained in example 5 (macromolecular compound after static dialysis)
The source is as follows: shanghai institute of pharmaceutical industry
Lot number and specification: 180921-4 (Paederia scandens extract-2 obtained in example 2), 181017-5# (dialysate of Paederia scandens extract (macromolecular compound after dynamic dialysis) obtained in example 3), 181017-6# (Paederia scandens extract (small molecular compound after static dialysis) obtained in example 5), 181017-7# (Paederia scandens extract (macromolecular compound after static dialysis) obtained in example 5)
Traits and storage conditions: light brown powder, storing at low temperature in dark place;
the preparation method of the medicine comprises the following steps: diluting with normal saline;
designing the dose: 100 mg/kg;
route of administration and volume: and (4) intragastric administration, and dosing according to the weight conversion.
1.1.2 Positive control
Name/abbreviated number: allopurinol tablets;
the source is as follows: shanghai Xin Wanxiang pharmaceutical Co., Ltd;
lot number and specification: (110802), 100 mg;
traits and storage conditions: tablets are dried and stored at room temperature;
designing the dose: 50 mg/kg;
route of administration and volume: and (4) intragastric administration, and dosing according to the weight conversion.
1.2 instruments and reagents
1.2.1 Experimental instruments
(1) Electronic analytical balance, model: sartorius ALC-210.3, manufacturer: siderelis corporation;
(2) high-speed centrifuge, model: 5810R, manufacturer: eppendorf (germany);
(3) full-automatic serum biochemical analyzer, model: 7080, manufacturer: calendar (japan);
(4) mouse scale, manufacturer: nanjing, Ma Neuli pharmaceutical instruments, Inc.;
1.2.2 Experimental reagents
A molding agent: potassium Oxonate (Adamas Reagent Co., Ltd.; LOT: P1275208);
solvent: physiological saline.
1.3 animals
1.3.1 animal sources
Strains and species: SD rat
Animal quality certification number: 2015000550327
Providing a unit: shanghai Si Laike laboratory animal responsibility Co., Ltd
Production license: SCXK (Shanghai) 2015-0005-
The unit of use: shanghai institute of pharmaceutical industry
The use license: SYXK 2014-40018
1.3.2 animal Specifications
SPF grade SD rats, 6-8 weeks old, 180-.
1.3.3 gender and number
And 36 males.
1.3.4 animal feeding
SPF-grade environmental animal laboratory, laboratory animals use license numbers: SYXK (Shanghai) 2014-0018. Animals were fed standard SPF-grade complete rat feed purchased from the experimental animal center of shanghai seliaceae, chinese academy. Drinking water for animals is supplied by drinking bottles, and the animals can drink water freely. 10-15 animals are raised in each cage, the room temperature of the animals is set to be 20-22 ℃, the humidity is set to be 40-70%, and the animals are alternately illuminated in light and shade for 12 hours. The padding is replaced at least 2 times per week, the feeding box is replaced at the same time, and the feeding box is replaced at any time when abnormal conditions occur. The sterilized drinking bottle and the bottle stopper are replaced every day, and the cage is sterilized for 1 time every two weeks. All the replaced and washed cages are sterilized by high pressure after being washed.
Second, Experimental methods
2.1 pharmaceutical formulation
(1) Test agent configuration: the tested sample is dissolved in 0.9% physiological saline, and prepared into suspension according to the dosage of 100mg/kg, and the suspension is stored in a refrigerator at 4 ℃ for standby.
(2) Potassium oxonate suspension: potassium oxonate powder is prepared into suspension by 0.9 percent of physiological saline according to the dosage of 300mg/kg, and the suspension is prepared on the day of the experiment.
(3) Allopurinol suspension: preparing into suspension according to the dose of 50mg/kg, and the preparation method is the same as that in (1).
2.2 Molding and grouping
2.2.1 animal groups
Animals were randomly assigned to 6 groups of 6 animals each after 1 week of acclimatization. The groups are normal control group, model group, positive drug group, 100mg/kg dose group.
2.2.2 Molding and administration
After grouping, except for the normal group, the rats in other groups are subjected to intraperitoneal administration of potassium oxonate suspension (1 ml/mouse), and are subjected to intragastric administration after 1h interval, and the rats in the normal and model groups are subjected to isovolumetric administration of normal saline.
2.2.3 index detection
Collecting blood from rat fundus venous plexus 1h after administration, centrifuging the obtained whole blood at 12000rpm for 5min to separate serum, inspecting with a Niri serum biochemical detector, and detecting the change of Uric Acid (UA) content in serum.
Third, experimental results
Table 1: effect of dialysate of Paederia scandens extract on SUA (acute hyperuricemia caused by Potassium Oxonate)
Comparison with the normal group:#P<0.05，##P<0.01，###P<0.001; comparison with model groups:*P<0.05，**P<0.01
the results are shown in the table, the blood uric acid concentration of the rats in the model group is very significantly different from that of the rats in the normal control group (P <0.001), and the modeling is successful; the positive allopurinol has a very significant inhibition effect (P <0.001) on the increase of SUA caused by the increase of endogenous uric acid, and the paederia scandens extract-2 obtained in example 2 also has a very significant uric acid reduction effect (P <0.001) on acute hyperuricemia rats. Meanwhile, the dialysate (small molecular compound after static dialysis) of the fevervine herb extract obtained in the example 5 also has a very significant effect (P <0.001) of reducing uric acid for the rat with acute hyperuricemia, and the effect is superior to that of the fevervine herb extract-2 obtained in the example 2, but the large molecular compound group obtained after dialysis of the fevervine herb extract has no obvious effect of reducing uric acid, which indicates that the active ingredient for reducing uric acid in the dialysate of the fevervine herb extract is a small molecular compound group.
Claims (11)
1. A dialysate of fevervine extract, wherein the fevervine extract comprises more than 60 wt% of iridoids, and the iridoids consist essentially of asperulosidic acid, asperuloside, indioside, paederosidic acid, and paederosidic acid methyl ester;
the preparation method comprises the following steps:
a) extracting herba Paederiae with ethanol to obtain extractive solution;
b) concentrating the extracting solution until no alcohol smell exists, performing macroporous adsorption resin chromatography for the first time, sequentially eluting with water and 80-90% ethanol, collecting ethanol eluent, performing reduced pressure concentration until no alcohol smell exists, performing macroporous adsorption resin chromatography for the second time, sequentially eluting with water and 25-35% ethanol, collecting ethanol eluent, and performing reduced pressure concentration to obtain a crude extract of the fevervine herb;
c) loading the herba Paederiae crude extract into polyamide chromatographic column, eluting with water, collecting eluate by stages, and drying under reduced pressure to obtain herba Paederiae extract;
d) dialyzing the fevervine extract through a 3500 Da-unit dialysis membrane, and recovering a fraction of small-molecule compounds permeating out of the membrane, which fraction of small-molecule compounds comprises asperuloside, indin, paederosidic acid and paederosidic acid methyl ester, to obtain a dialysate of the fevervine extract.
2. The dialysate of fevervine herb extract of claim 1, wherein the macroporous adsorbent resin is applied for the first time in step b), and then the dialysate is sequentially eluted with water and 85% ethanol, and the 85% ethanol eluate is collected.
3. The dialysate of fevervine herb extract according to claim 1, wherein the macroporous adsorbent resin is again loaded in step b) and then sequentially eluted with water and 30% ethanol, and the 30% ethanol eluate is collected.
4. The dialysate of fevervine herb extract of claim 1, wherein the macroporous adsorbent resin of step b) is type D101.
5. The dialysate of fevervine herb extract of claim 1, wherein the column diameter-to-height ratio of the macroporous adsorbent resin in step b) is 1:8 to 1: 12.
6. The dialysate of fevervine herb extract according to claim 1, wherein the flow rates of the first and second loading in step b) are both 1.0-2.0BV/h and the elution flow rate is 4-6 BV/h.
7. The dialysate of fevervine herb extract according to claim 1, wherein the column size ratio of the polyamide column in step c) is 1:8 to 1:12, and the particle size is 30 to 50 mesh.
8. A method for preparing a dialysate of fevervine herb extract comprising the steps of:
a) extracting herba Paederiae with ethanol to obtain extractive solution;
b) concentrating the extracting solution until no alcohol smell exists, performing macroporous adsorption resin chromatography for the first time, sequentially eluting with water and 80-90% ethanol, collecting ethanol eluent, performing reduced pressure concentration until no alcohol smell exists, performing macroporous adsorption resin chromatography for the second time, sequentially eluting with water and 25-35% ethanol, collecting ethanol eluent, and performing reduced pressure concentration to obtain a crude extract of the fevervine herb;
c) loading the herba Paederiae crude extract into polyamide chromatographic column, eluting with water, collecting eluate by stages, and drying under reduced pressure to obtain herba Paederiae extract;
d) dialyzing the fevervine extract through a 3500 Da-unit dialysis membrane, and recovering a fraction of small-molecule compounds permeating out of the membrane, which fraction of small-molecule compounds comprises asperuloside, indin, paederosidic acid and paederosidic acid methyl ester, to obtain a dialysate of the fevervine extract.
9. Use of a dialysate of fevervine extract of claims 1-7 or of fevervine extract obtained by the method of claim 10 in the manufacture of a medicament for reducing uric acid.
10. Use of a dialysate of fevervine extract of any one of claims 1 to 7 or obtained by the method of claim 8 in the manufacture of a medicament for the treatment of gouty arthritis.
11. Use of a dialysate of fevervine extract of any one of claims 1 to 7 or obtained by the method of claim 8 in the manufacture of a medicament for the treatment of hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910488224.4A CN112043756A (en) | 2019-06-05 | 2019-06-05 | Dialysate of fevervine extract, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910488224.4A CN112043756A (en) | 2019-06-05 | 2019-06-05 | Dialysate of fevervine extract, preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112043756A true CN112043756A (en) | 2020-12-08 |
Family
ID=73609773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910488224.4A Pending CN112043756A (en) | 2019-06-05 | 2019-06-05 | Dialysate of fevervine extract, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112043756A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846784A (en) * | 2011-06-23 | 2013-01-02 | 宁波大昌药业有限公司 | Paederia scandens water extract, and preparation method and application thereof |
| CN103242390A (en) * | 2012-02-08 | 2013-08-14 | 鲁南制药集团股份有限公司 | Method for extracting methyldeactylasperulosidate and Scandoside methyl ester |
| CN104435226A (en) * | 2014-11-06 | 2015-03-25 | 宁波大昌药业有限公司 | Paederia scandens extract and application thereof |
-
2019
- 2019-06-05 CN CN201910488224.4A patent/CN112043756A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102846784A (en) * | 2011-06-23 | 2013-01-02 | 宁波大昌药业有限公司 | Paederia scandens water extract, and preparation method and application thereof |
| CN103242390A (en) * | 2012-02-08 | 2013-08-14 | 鲁南制药集团股份有限公司 | Method for extracting methyldeactylasperulosidate and Scandoside methyl ester |
| CN104435226A (en) * | 2014-11-06 | 2015-03-25 | 宁波大昌药业有限公司 | Paederia scandens extract and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats | |
| WO2020238642A1 (en) | Inclusion compound containing non-psychoactive cannabinoid and method for preparation thereof | |
| KR20200121062A (en) | A Method for Purifying Plant-Derived Extracellular Vesicles | |
| US20130310554A1 (en) | Aqueous Diphase Solvent System for Preparing High-Purity Polysaccharides | |
| CN101270101B (en) | Method for preparing potassium sodium dehydroandroan drographolide succinate for injection and its freeze-dried injection | |
| US20040109907A1 (en) | Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles | |
| CN102805767B (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN107929544B (en) | Preparation method and application of mileanine part and monomer in bletilla plants | |
| CN1323797A (en) | Chinese chestnut flower flavone compound and its extraction process | |
| CN112043755A (en) | Paederia scandens extract, preparation method and application thereof | |
| CN112043756A (en) | Dialysate of fevervine extract, preparation method and application thereof | |
| CN104095809A (en) | Pharmaceutical composition of clindamycin phosphate injection and preparation method | |
| CN103142474B (en) | With the composition and method of making the same that high purity bilobalide B is active component | |
| CN112957344B (en) | Nanometer preparation containing passionflower flavone and its preparation method | |
| CN101190906B (en) | Method for preparing carthamin yellow carthamus B and application thereof | |
| Jamali et al. | Salicylate excretion in breast milk | |
| CN112047983B (en) | Paedenic acid monomer compound, preparation method and application thereof | |
| CN112047989B (en) | Paedenin methyl ester monomer compound, preparation method and application thereof | |
| CN103191309B (en) | Mailuoning granule and preparation method | |
| CN113616596B (en) | Paclitaxel liposome pharmaceutical composition and preparation method thereof | |
| CN110898116B (en) | Paederia scandens extract and separation preparation method and application thereof | |
| CN102319420A (en) | Application of soft-shelled turtle peptide in preparation of medicines | |
| CN112047988B (en) | Paederoside monomer compound, preparation method and application thereof | |
| CN101480423A (en) | Method for preparing salvia root extract rich in salvianolic acid A | |
| CN101926835B (en) | Method for extracting gingko total terpene lactones and injection containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |